Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences is supported by a diversified late-stage clinical pipeline, with ABI-6250 now extending from HDV into PBC and PSC, where management sees approximately $2 billion-plus and $1 billion-plus U.S. peak-year potential, respectively, and a Phase 2 basket trial is anticipated in 1Q27 with data in 1H28. The program’s appeal is strengthened by Phase 1a data showing a four-day half-life, about seven-fold accumulation with once-daily dosing, and no pruritus adverse events, while the Gilead-selected GS-1179 HPI program adds optionality into recurrent genital herpes and even HIV PrEP-related prevention settings. Financially, the company ended 2Q26 with $320.4 million in cash and investments after a May 22 offering, and expects runway into 2029 including the first $75 million Gilead collaboration extension payment due in 4Q26.

Assembly Biosciences is a pre-profitability clinical-stage biotech with $226.6M in cash at the end of 1Q 2026, and while management says that funds operations into 2028, that runway excludes possible GILD payments and warrant exercises and was already supplemented by a May 2026 offering that raised about $115M. The core weakness is that the company is not expected to be profitable on a continuing basis until 2032, implying a likely need for additional financing before then that could dilute existing shareholders. On top of that, delays, clinical setbacks, reimbursement hurdles, or weak commercial execution for ABI-5366, ABI-1179, or ABI-6250 could materially reduce sales potential and pressure valuation.